The U.S. Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults. Victoza is intended to help lower blood sugar levels along with diet, exercise, and selected other diabetes medicines. It is not recommended as initial therapy in patients who have not achieved adequate diabetes control on diet and exercise alone. Insulin is a hormone that helps prevent sugar (glucose) from building up in the blood. People with type 2 diabetes have difficulty making and using insulin. Victoza is in a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists that help the pancreas make more insulin after eating a meal.
Having diabetes can feel like a balancing act among blood glucose (sugar) levels, food, exercise and the ways in which each of these elements affects day-to-day life. Add to this more than 12 hours of dancing each day in pointe shoes, late-night performances and flip-flopping diagnoses, and it's no wonder that ballerina Zippora Karz "felt like a human yo-yo." Diabetes Forecast, the consumer magazine of the American Diabetes Association, interviews Karz about her experience in the New York City Ballet with type 1 diabetes. As a 21-year-old member of the New York City Ballet in 1987, Karz began to experience some common symptoms of diabetes, such as extreme thirst, constant hunger, and frequent urination.
More than half of people with diabetes who take insulin injections to control their diabetes say they have intentionally skipped an injection, with one-fifth of them reporting that they do so "sometimes" or "often, " according to a study being published this month in Diabetes Care. Using an Internet survey of more than 500 U.S. adults, the study found that 57% of survey respondents with either type 1 or type 2 diabetes purposefully failed to take their insulin shots at least occasionally. It also found that older patients, those who were disabled, those who followed a healthy diet and those with higher household incomes were more likely to take their shots at the frequency prescribed.
American Diabetes Association Welcomes Newest Volunteer Leader To 2010 Research Foundation Board Of Directors
The American Diabetes Association, the nation's largest and leading voluntary health organization in the fight against diabetes, is pleased to announce the newest member of its Research Foundation Board of Directors for 2010 Kenneth Moritsugu, MD, MPH of Falls Church, Virginia. Moritsugu, a native of Honolulu, Hawaii, is the current Chairman of the Johnson & Johnson Diabetes Institutes and Vice President for Global Strategic Affairs of the Johnson & Johnson Family of Diabetes Companies. Moritsugu had a 37 year career in the Commissioned Corps of the US Public Health Service. He was the Acting Surgeon General of the United States in 2002 and 2006-2007, in addition to serving as Deputy Surgeon General to Dr.
Depression raises risks of advanced and severe complications from diabetes, according to a prospective study of Group Health primary-care patients in western Washington. These complications include kidney failure or blindness, the result of small vessel damage, as well as major vessel problems leading to heart attack or stroke. The findings were published this week in Diabetes Care, a scientific journal of the American Diabetes Association. The study was conducted by scientists from the Group Health Research Institute, Seattle; the University of Washington (UW) School of Medicine and School of Public Health, and the Veterans Affairs Puget Sound Health Care System.
In patients with type 2 diabetes, silent cerebral infarction (SCI) small areas of brain damage caused by injury to small blood vessels signals an increased risk of progressive kidney disease and kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). If SCI is present in the brain, it could be an indicator that small-vessel damage is present in the kidneys as well, suggests the new study by Takashi Uzu, MD (Shiga University School of Medicine, Otsu, Japan). Uzu comments, "Silent cerebral infarction may be a new marker to identify patients who are risk for declining kidney function.